+ Watch CRME
on My Watchlist
Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.
Despite some obvious speed bumps, I think Cardiome remains significantly undervalued given the prospects for both IV and oral vernakalant. While the process is certainly frustrating for impatient investors, the eventual payoff is likely to be very high. I wouldn't be surprised if the share price is four or five times higher in two years, and there's no telling when in that two years the rise will occur. I closed one outperform as the S&P drop gave me a positive score, and I've now re-entered at a lower price hoping for an eventual three or four hundred points. The bottom line is that the vernakalant data is good, the need for the drug is certainly there, and there's definitely potential for it to be a game changer in the emergency management of atrial fibrillation. I see Cardiome, Arena, and Ligand as the most undervalued small cap biotechs in the current market.
For someone who asked, I remain bullish on Cardiome and continue to hold 5000 shares bought about a year ago with a cost basis of 4. I continue to believe that vernakalant is an effective drug with a large potential market. I still do not understand the incredible slowness with which its development is proceeding. This is a drug that several cardiologists I know are aware of and have been waiting for for three years. However, data from the latest phase III trial is not expected until H1 2011. I will try and hold my investment until the share price hits 8 and I've made $20000, but I definitely won't allow myself to go back into the red. I've put a stop in at 5.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions